Financials

  • Market Capitalization 69.15 B
  • Employee 15 K
  • Founded 1988
  • CEO Leonard Schleifer
  • Website www.regeneron.com
  • Headquarter New York, United States
  • FIGI BBG000C734W3
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
18.61
Price to sales ratio
5.84

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
125
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
481.31 USD-0.84%-9.09%+9.38%+3.06%122.16 B USD
294
ARGX
argenx SE - American Depositary Shares
871.80 USD-0.66%-6.02%-3.13%+56.02%53.95 B USD
382
RVMD
Revolution Medicines, Inc. - Common Stock
181.70 USD-2.77%-4.07%+18.73%+227.98%38.63 B USD
386
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
286.24 USD-4.19%-9.06%-0.94%-9.11%38.22 B USD

Frequently asked questions about Regeneron Pharmaceuticals, Inc. - Common Stock

What is the Regeneron Pharmaceuticals, Inc. - Common Stock stock price today?

The current price of Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) is 659.61. Over the past 24 hours, the stock has changed by -0.74%. Follow the REGN chart for real-time price dynamics.

What is the stock ticker of Regeneron Pharmaceuticals, Inc. - Common Stock?

Regeneron Pharmaceuticals, Inc. - Common Stock trades under the ticker REGN. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Regeneron Pharmaceuticals, Inc. - Common Stock stock going up?

REGN has changed by +1.49% over the last week, +8.33% over the last month, and +16.52% over the last year. Review the chart to see whether the current move is part of a broader trend.

Does Regeneron Pharmaceuticals, Inc. - Common Stock release financial reports?

Yes. You can track Regeneron Pharmaceuticals, Inc. - Common Stock financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

What was Regeneron Pharmaceuticals, Inc. - Common Stock net income for the last quarter?

Regeneron Pharmaceuticals, Inc. - Common Stock reported net income of 727.2 M for the last quarter. The previous quarter showed 844.6 M, which means net income changed by -13.90%.

How many employees does Regeneron Pharmaceuticals, Inc. - Common Stock have?

As of the latest available data, Regeneron Pharmaceuticals, Inc. - Common Stock has 15.41 K employees. Workforce size can provide additional context about the company's scale and operations.

What is Regeneron Pharmaceuticals, Inc. - Common Stock EBITDA?

Regeneron Pharmaceuticals, Inc. - Common Stock EBITDA is 766.1 M, and its EBITDA margin is 21.25%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Regeneron Pharmaceuticals, Inc. - Common Stock stock?

You can buy Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Regeneron Pharmaceuticals, Inc. - Common Stock stock?

Investing in Regeneron Pharmaceuticals, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the REGN chart and related analysis on metatrader.com as part of your research.

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

News